<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01412372</url>
  </required_header>
  <id_info>
    <org_study_id>39402</org_study_id>
    <nct_id>NCT01412372</nct_id>
  </id_info>
  <brief_title>The Effect of Long-Acting Mesalamine on Post-Infective Irritable Bowel Syndrome- A Pilot Study</brief_title>
  <acronym>Mesalamine</acronym>
  <official_title>The Effect of Long-Acting Mesalamine on Post-Infective Irritable Bowel Syndrome- A Pilot Study</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>University of Utah</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Shire Human Genetic Therapies, Inc.</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
  </sponsors>
  <source>University of Utah</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this study is to evaluate the effects of long acting mesalamine (Lialda) in
      patients with Post-Infective Irritable Bowel Syndrome (PI-IBS). The investigators will
      evaluate gastrointestinal symptoms, IBS specific quality of life (IBS-QOL), and plasma
      cytokines before and after treatment with Lialda.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      This study will test long acting mesalamine in the management of PI-IBS. It has the potential
      to improve QOL and perhaps gastrointestinal symptoms, in patients with PI-IBS. The results of
      this study, if positive, will provide preliminary data for a large scale clinical trial.

      This study will also provide information about plasma cytokines in patients with PI-IBS and
      whether improvement in symptoms correlates with improvement in plasma cytokines.
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date>June 2010</start_date>
  <completion_date type="Anticipated">September 2018</completion_date>
  <primary_completion_date type="Anticipated">September 2018</primary_completion_date>
  <phase>Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Triple (Participant, Care Provider, Investigator)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Change from baseline in gastrointestinal symptoms and IBS specific quality of life after an 8 week treatment period</measure>
    <time_frame>Baseline and 8 weeks</time_frame>
  </primary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">68</enrollment>
  <condition>Irritable Bowel Syndrome</condition>
  <arm_group>
    <arm_group_label>Placebo</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>This arm will include those who are randomized to the placebo</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Mesalamine</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>This arm is for subjects randomized to the study drug, Mesalamine</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Mesalamine</intervention_name>
    <description>2 1.2g tablets once daily for 8 weeks. Patients randomized 50/50 to either Mesalamine or the Placebo</description>
    <arm_group_label>Mesalamine</arm_group_label>
    <other_name>Lialda</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Placebo</intervention_name>
    <description>This is an inactive pill</description>
    <arm_group_label>Placebo</arm_group_label>
    <other_name>Inactive drug</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

        Inclusion Criteria

          1. Men and women age 18-75 years

          2. Rome III criteria for IBS

          3. Symptom onset after apparent acute gastroenteritis

          4. Symptoms of 6 months or greater duration

          5. Normal gross appearance of the colonic mucosa other than erythema

          6. Negative markers for celiac disease and inflammatory bowel disease

          7. Normal thyroid function and serum calcium

          8. Stable medication regimens for other medical conditions.

        Exclusion Criteria:

          1. Age &lt;18 or &gt;75 years

          2. Previous diagnosis of or history compatible with IBS

          3. Constipation-predominant IBS.

          4. Clinically significant chronic cardiac, pulmonary, hepatic, renal dysfunction or HIV

          5. History of/or presence of malignancy

          6. Current evidence of any gastrointestinal disorder such as celiac disease, inflammatory
             bowel disease, chronic pancreatitis, scleroderma, HIV, small bowel or colonic
             resection, paraplegia or quadriplegia. .

          7. Current evidence of drug or alcohol abuse as judged by the investigator

          8. Allergy to mesalamine or aspirin

          9. Investigator perception of patient's inability to comply with the study protocol

         10. Unstable psychiatric disease

         11. Recent change in gastrointestinal medications
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>75 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Ashok Tuteja</last_name>
    <role>Principal Investigator</role>
    <affiliation>Gastroenterology</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Jaya Vijayan, M.B.B.S.</last_name>
    <email>jaya.vijayan@hsc.utah.edu</email>
  </overall_contact>
  <location>
    <facility>
      <name>University of Utah</name>
      <address>
        <city>Salt Lake City</city>
        <state>Utah</state>
        <zip>84132</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Jaya Vijayan, M.B.B.S.</last_name>
      <email>jaya.vijayan@hsc.utah.edu</email>
    </contact>
    <investigator>
      <last_name>Ashok Tuteja, M.D.</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>January 2018</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>June 24, 2011</study_first_submitted>
  <study_first_submitted_qc>August 5, 2011</study_first_submitted_qc>
  <study_first_posted type="Estimate">August 9, 2011</study_first_posted>
  <last_update_submitted>January 2, 2018</last_update_submitted>
  <last_update_submitted_qc>January 2, 2018</last_update_submitted_qc>
  <last_update_posted type="Actual">January 4, 2018</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>University of Utah</investigator_affiliation>
    <investigator_full_name>Ashok K. Tuteja</investigator_full_name>
    <investigator_title>Associate professor of medicine</investigator_title>
  </responsible_party>
  <keyword>Irritable Bowel Syndrome</keyword>
  <keyword>Diarrhea</keyword>
  <keyword>Mesalamine</keyword>
  <keyword>Gastroenteritis</keyword>
  <keyword>abdominal pain</keyword>
  <keyword>hypersensitivity</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Syndrome</mesh_term>
    <mesh_term>Irritable Bowel Syndrome</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Mesalamine</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

